Idiopathic pulmonary fibrosis (IPF) is a fatal disease in which the normal alveolar network is
gradually replaced by fibrotic scars. Current evidence suggests that metabolic alterations …

Rationale: Dysregulation of cellular metabolism has been shown to participate in several
pathologic processes. However, the role of metabolic reprogramming is not well appreciated …

Idiopathic pulmonary fibrosis (IPF) is a disease with relentless course and limited
therapeutic options. Nintedanib (BIBF-1120) is a multiple tyrosine kinase inhibitor recently …

Background Idiopathic pulmonary fibrosis (IPF) is a serious interstitial lung disease with a
complex pathogenesis and high mortality. The development of new drugs is time-consuming …

Objectives Anlotinib hydrochloride (AL3818) is a novel multitarget tyrosine kinase inhibitor
which has the same targets as nintedanib, an effective drug has been approved for the …

Aloperine is a quinolizidine alkaloid extracted from Sophora alopecuroides. It has been
proven to alleviate oxidative stress and effectively promote tumor cell apoptosis in mice …

Introduction: Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal lung disease with a
poor prognosis and increasing incidence. Pirfenidone and nintedanib are the only approved …

Idiopathic pulmonary fibrosis (IPF) is a chronic lung disorder that is characterized by
aberrant tissue remodeling and the formation of fibroblastic foci that are composed of …

Background Idiopathic pulmonary fibrosis (IPF) is a fatal respiratory disease characterized
by aberrant fibroblast activation and progressive fibrotic remodelling of the lungs. Though …

Pulmonary fibrosis is a progressive and intractable lung disease with fibrotic features that
affects alveoli elasticity, which leading to higher rates of hospitalization and mortality …